Terns Pharmaceuticals, Inc. (TERN) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Foster City, CA, United States. The current CEO is Melita Sun Jung.
TERN has IPO date of 2021-02-05, 59 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $4.75B.
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule therapies for non-alcoholic steatohepatitis (NASH) and obesity. The company's pipeline includes TERN-101, a farnesoid X receptor agonist in Phase IIa trials for NASH; TERN-201, a vascular adhesion protein-1 inhibitor in Phase Ib development; TERN-501, a thyroid hormone receptor beta agonist in Phase I trials; and TERN-601, an oral Glucagon-Like Peptide-1 receptor agonist program targeting NASH and metabolic diseases. Founded in 2016 and headquartered in Foster City, California, Terns is advancing both single-agent and combination therapy candidates to address significant unmet medical needs in metabolic disease treatment.
